SELECTED LIST OF DRUGS: HEOR VALUE PROPOSITION STUDIES/ HTA GLOBAL AND LOCAL PREPARATIONS/

PATIENT REPORTED OUTCOMES/ QOL AND CLINICAL /REGULATORY WORK

Company Drug HEOR Value Propositions

HTA Submissions Patient Reported Outcomes/ Quality of Life

NDA/ Regulatory CSR

CNS

Ortho-McNeil Tapentadol US HCUP/ Premier PRO

Janssen-Cilag Risperidone Australia/ published Canada/ Australia Health State Utilities

Janssen-Cilag Risperidone Contra Australia Australia

AstraZeneca Quetiapine Canada/ UK Canada Health State Utilities

QUEST Trial

Eisai Perampanel Global Global Health State Utilities

GSK Lamotrigine US

BMS Aripiprazole US/ Pharmerit data

Cardiovascular

Sankyo Olmesartan US/ Managed care data

US-AMCP CS866-306

Daichii-Sankyo Olmesartan US/ Germany/ EU-5 CS866-411

BMS Irbesartan Global Global Multiple Trials

Sanofi/BMS Irbesartan Europe

Nycomed Olmesartan Norway

Sanofi Ramapril Australia

Abbott Niacin Australia

Daichii-Sankyo Colesavelam US US AMCP

Servier Ivabradine Global Australia

Atherosclerosis

Sanofi/ BMS Clopidogrel Global Global CAPRIE

Sanofi/ BMS Clopidogrel Australia (ACS)

Endocrinology

Sanofi Insulin Glargine Australia Australia/ US

Sanofi U300 US/ UK

Daichii-Sankyo Colesavelam US WEL 301, 302, 303

Oncology

AstraZeneca Anastrozole Canada/ UK EORTC/ Health State Utilities

AstraZeneca Zoladex Canada/ UK EORTC/ Health State Utilities

AstraZeneca Faslodex Global EORTC

BMS Dasatinib US

Merck Pembrolizumab Global

Eisai Eribulin Global Global EORTC FDA/ EMA

Eisai Lenvatinib Global

Eisai Farlatuzamab EORTC FDA/ EMA

Sanofi Taxotere Australia Health State Utilities

Rheumatology

BMS Abatacept US Indirect Economics

Respiratory

AstraZeneca Zafirlukast Canada ASUI